Research Paper Volume 15, Issue 11 pp 4889—4905
Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
Figure 2. Clinicopathologic features of LUAD and somatic mutation in KRAS-mutated and KRAS-wild groups. (A) The comparison of clinicopathologic features between KRAS-mutated and KRAS-wild groups. (B) The waterfall plot of top 10 mutation genes in KRAS-wild group. (C) The waterfall plot of top 10 mutation genes in KRAS-mutated group. (D) The forest plot of genes with different mutation frequencies between the KRAS-mutated and KRAS-wild groups. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).